What’s new in the management of acute severe asthma?

From a recently published update:

Recent findings: β2-agonist heliox-driven nebulization significantly increased by 17% [95% confidence interval (CI) 5.2–29.4] peak expiratory flow, and decreased the rate of hospital admissions (risk ratio 0.77, 95% CI 0.62–0.98), compared with oxygen-driven nebulization. Other findings indicate that there is no robust evidence to support the use of intravenous or nebulized magnesium sulphate in adults with severe acute asthma, and that levalbuterol was not superior to albuterol regarding efficacy and safety in individuals with acute asthma. Finally, hyperlactatemia developed during the first hours of acute asthma treatment has a high prevalence, is related with the use of β2-agonists and had no clinical consequences.